WIKIMEDIA, URCOMUNICACIONThrough its latest acquisition effort, Irish drugmaker Shire is paying approximately $5.9 billion for Massachusetts-based Dyax Corp., a biotech firm focused on a rare disease called hereditary angioedema (HAE). Dyax’s lead candidate, DX-2930, is a fully humanized monoclonal antibody targeting plasma kallikrein, which is dysregulated in HAE. According to a statement from Shire, DX-2930 is expected to enter Phase 3 trials by the end of this year.

“Shire’s expertise and proven rare disease patient identification and management capabilities make it the ideal partner to efficiently bring DX-2930 to HAE patients worldwide,” Gustav Christensen, president and chief executive of Dyax, said in the statement.

This January, Shire paid $5.2 billion for New Jersey-based NPS Pharmaceuticals. In the statement, Shire Chief Executive Officer Flemming Ornskov said his firm is now eyeing other acquisitions, including that of the Illinois-based biopharma Baxalta.

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?